Clinical Trial Update: Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a low-dose combination of linagliptin and metformin to prevent diabetes in individuals with prediabetes and insulin resistance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance
• Prediabetes

Drugs mentioned

• Linagliptin + Metformin (low-dose combination)

Snippet

Sponsor: Universidad de Guanajuato | Conditions: Prediabetic State, Insulin Resistance | Phase 3 | Status: UNKNOWN